Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

Clarke, N.W.; Ali, Amin; C. Ingleby, Fiona; Hoyle, Alex; Amos, Claire; Attard, Gerhardt; Brawley, Chris; Calvert, J.; Chowdhury, S.; Cook, Audrey; Cross, William; P. Dearnaley, David; Douis, Hassan; C. Gilbert, Duncan; Gillessen, Silke; J. Jones, Robert; E. Langley, Ruth; Macnair, Archie; Malik, Zafar; D. Mason, Malcolm; Matheson, David; Millman, R.; Parker, Chris; Ritchie, A.W.S.; Rush, Hannah; M. Russell, John; E. Brown, Janet; Beesley, S.; Birtle, Alison; Capaldi, Lisa; Gale, Joanna; Gibbs, Stephanie; Lydon, Anna; Nikapota, Ashok; Omlin, Aurelius; M. O’Sullivan, Joe; Parikh, Omi; Protheroe, Andrew; Rudman, Sarah; Srihari, Narayanan; Simms, Matthew; Tanguay, Jacob; Tolan, Shaun; Wagstaff, John; Wallace, Jan; Wylie, J.; Zarkar, Anjali; R. Sydes, Matthew; Parmar, Mahesh; D. James, Nicholas

doi:10.1093/annonc/mdz396

Public

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

Published in Annals of Oncology • Sep 9, 2019

Authors:

N.W. Clarke

Amin Ali

Fiona C. Ingleby

Abstract

BACKGROUND: STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term outcomes stratified by metastatic burden for M1 patients. METHOD...

Subject

Medicine

Docetaxel

Prostate cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!